At 12 months after intracoronary stent placement, antithrombotic therapy is suggested as for patients with AF and stable coronary artery disease (see section 3.1). For patients with AF at low to intermediate risk of stroke (eg, CHADS2 score of 0 or 1) during the rst 12 months after placement of an intra- coronary stent (bare metal or drug eluting), we suggest dual antiplatelet therapy rather than triple therapy (Grade 2C). At 12 months after intracoronary stent placement, antithrombotic therapy is suggested as for patients with AF and stable coronary artery disease (see section 3.1). Remarks: Patients who place an exceptionally high value on stroke reduction and a low value on avoiding trials including 2,436 patients found that a 30- to 42-day course of ticlopidine plus aspirin vs warfa- rin plus aspirin reduced the 30- to 42-day risk of nonfatal MI (relative risk, 0.50; 95% CI, 0.30-0.83; number needed to treat, 55) and revascularization (relative risk, 0.29; 95% CI, 0.16-0.56; number needed to treat, 33) with a possible reduction in major bleed- ing (relative risk, 0.36; 95% CI, 0.14-1.02) (see Table 11 in Vandvik et al,108 sections 3.1-3.5).114 Based on these data, we recommend aspirin and clopidogrel over warfarin plus aspirin for a nite period following stent placement. For patients with AF receiving oral anticoagulation who undergo place- ment of an intracoronary stent, the dilemma arises about whether patients should be continued on oral anticoagulation during the time they are recom- mended to be on dual antiplatelet therapy, given the lack of direct evidence from RCTs addressing this question. 